Eli Lilly: Lack of Epidemiology, Causation Evidence 'Frustrating' Zyprexa MDL

NEW YORK - Charging that there are 'serious epidemiological problems' with the cases, Zyprexa manufacturer Eli Lilly recently requested that the MDL court issue an order requiring a plaintiffs' law firm to show cause why they should not have to provide evidence of individual causation for each of its clients. In re Zyprexa Products Liability Litigation, MDL No. 1596 (E.D. N.Y.).

The request came in the form of a Nov. 17 letter written by Lilly's counsel to Judge Jack B. Weinstein, who is presiding over the Zyprexa MDL in the U.S. District Court for the Eastern District of New York.